Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer...
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
Seaking AlphaSeeking Alpha / Seaking Alpha 17 hours ago 1 Views
Comments